Peripheral Cytokines and Chemokines in Alzheimer's Disease

被引:121
作者
Lee, Kang Soo [2 ,3 ]
Chung, Ji Hyung [4 ,5 ]
Choi, Tae Kyou [2 ]
Suh, Shin Young [2 ]
Oh, Byoung Hoon [3 ]
Hong, Chang Hyung [1 ,6 ]
机构
[1] Ajou Univ, Sch Med, Dept Psychiat, Suwon 443749, South Korea
[2] CHA Univ, Bundang Cha Med Ctr, Dept Psychiat, Songnam, South Korea
[3] Yonsei Univ, Grad Sch, Dept Med, Seoul 120749, South Korea
[4] Yonsei Integrat Res Inst Cerebral & Cardiovasc Di, Seoul, South Korea
[5] Yonsei Univ Hlth Syst, Seoul, South Korea
[6] Ajou Univ Hosp, Memory Impairment Ctr, Suwon, South Korea
关键词
Alzheimer's disease; Inflammation; Cytokines; Chemokines; Biomarkers; NECROSIS-FACTOR-ALPHA; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; INFLAMMATORY MARKERS; SERUM INTERLEUKIN-6; VASCULAR DEMENTIA; MULTIINFARCT DEMENTIA; INTERFERON-GAMMA; TNF-ALPHA; PLASMA;
D O I
10.1159/000245156
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
A chronic inflammatory process has been implicated in the neuropathology of Alzheimer's disease (AD). The present review focuses on the current knowledge of circulating serum and plasma biomarkers of AD that are linked to inflammatory reactions. There is abundant evidence that inflammatory mechanisms within the central nervous system contribute to cognitive impairment via cytokine-mediated interactions between neurons and glial cells. Interleukins 1, 4, 6, 10, 12, 16, and 18, tumour necrosis factor, and several chemokines have been suggested as biomarkers of AD. Nonetheless, data on circulating cytokine levels are somewhat inconsistent with regard to peripheral cytokine dysregulation in AD. In summary, definite statements concerning differences in inflammatory biomarkers between controls and AD patients will require the use of sensitive multiplex assays in large patient groups in conjunction with measures of disease severity. Copyright (c) 2009 S. Karger AG, Basel
引用
收藏
页码:281 / 287
页数:7
相关论文
共 50 条
[1]   Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease [J].
Alvarez, XA ;
Franco, A ;
FernandezNovoa, L ;
Cacabelos, R .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1996, 29 (2-3) :237-252
[2]  
AMBI F, 2004, J CLIN PSYCHOPHARM, V24, P314
[3]   Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease [J].
Angelis, P ;
Scharf, S ;
Mander, A ;
Vajda, F ;
Christophidis, N .
NEUROSCIENCE LETTERS, 1998, 244 (02) :106-108
[4]   CYTOKINES IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA [J].
Angelopoulos, P. ;
Agouridaki, H. ;
Vaiopoulos, H. ;
Siskou, E. ;
Doutsou, K. ;
Costa, V. ;
Baloyiannis, S. I. .
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2008, 118 (12) :1659-1672
[5]  
Baranowska-Bik A, 2008, NEUROENDOCRINOL LETT, V29, P75
[6]   Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease [J].
Bermejo, Paloma ;
Martin-Aragon, Sagrario ;
Benedi, Juana ;
Susin, Cristina ;
Felici, Ernanuela ;
Gil, Pedro ;
Ribera, Jose Manuel ;
Villar, Angel M. .
IMMUNOLOGY LETTERS, 2008, 117 (02) :198-202
[7]   Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias [J].
Blasko, I ;
Lederer, W ;
Oberbauer, H ;
Walch, T ;
Kemmler, G ;
Hinterhuber, H ;
Marksteiner, J ;
Humpel, C .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2006, 21 (01) :9-15
[8]   Costimulatory effects of interferon-γ and interleukin-1β or tumor necrosis factor α on the synthesis of aβ1-40 and aβ1-42 by human astrocytes [J].
Blasko, I ;
Veerhuis, R ;
Stampfer-Kountchev, M ;
Saurwein-Teissl, M ;
Eikelenboom, P ;
Grubeck-Loebenstein, B .
NEUROBIOLOGY OF DISEASE, 2000, 7 (06) :682-689
[9]   Cerebrospinal Fluid Protein Biomarkers for Alzheimer's Disease [J].
Blennow K. .
NeuroRX, 2004, 1 (2) :213-225
[10]   Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients [J].
BlumDegen, D ;
Muller, T ;
Kuhn, W ;
Gerlach, M ;
Przuntek, H ;
Riederer, P .
NEUROSCIENCE LETTERS, 1995, 202 (1-2) :17-20